O. Barbier, I. Pineda-torra, Y. Duguay, C. Blanquart, J. C. Fruchart et al., Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis, Arterioscler. Thromb. Vasc. Biol, vol.22, issue.5, pp.717-726, 2002.
URL : https://hal.archives-ouvertes.fr/inserm-02912615

A. Aranda and A. , Nuclear hormone receptors and gene expression, Physiol. Rev, vol.81, issue.3, pp.1269-1304, 2001.

S. Kliewer, K. Umesono, D. J. Noonan, R. A. Heyman, and R. M. Evans, Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors, Nature, issue.6389, pp.771-774, 1992.

R. T. Gampe, V. G. Montana, M. H. Lambert, A. B. Miller, R. K. Bledsoe et al., Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors, Mol. Cell, vol.5, issue.3, pp.545-555, 2000.

W. Bourguet, P. Germain, and H. Gronemeyer, Nuclear receptor ligandbinding domains: three-dimensional structures, Trends Pharmacol. Sci, vol.21, issue.10, pp.381-388, 2000.

J. C. Fruchart, P. Duriez, and B. Staels, Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis, Curr. Opin. Lipidol, vol.10, issue.3, pp.245-257, 1999.

T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, The PPARs: from orphan receptors to drug discovery, J. Med. Chem, vol.43, issue.4, pp.527-550, 2000.

W. R. Oliver, J. L. Shenk, M. R. Snaith, C. S. Russell, K. D. Plunket et al., A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport, Proc. Natl. Acad. Sci. U.S.A, vol.98, issue.9, pp.5306-5311, 2001.

B. D. Darimont, R. L. Wagner, J. W. Apriletti, M. R. Stallcup, P. J. Kushner et al., Structure and specificity of nuclear receptor-coactivator interactions, Genes Dev, vol.12, issue.21, pp.3343-3356, 1998.

H. E. Xu, T. B. Stanley, V. G. Montana, M. H. Lambert, B. G. Shearer et al., Structural basis for antagonist-mediated recruitment of nuclear corepressors by PPARalpha, Nature, issue.6873, pp.813-817, 2002.

A. Shalev, C. A. Siegrist-kaiser, P. M. Yen, W. Wahli, A. G. Burger et al., The peroxisome proliferator-activated receptor alpha is a phosphoprotein: regulation by insulin, Endocrinology, vol.137, issue.10, pp.4499-4502, 1996.

C. E. Juge-aubry, E. Hammar, C. Siegrist-kaiser, A. Pernin, A. Takeshita et al., Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent transactivating domain, J. Biol. Chem, vol.274, issue.15, pp.10505-10510, 1999.

P. M. Barger, A. C. Browning, A. N. Garner, and D. P. Kelly, p38 mitogen-activated protein kinase activates peroxisome proliferatoractivated receptor alpha: a potential role in the cardiac metabolic stress response, J. Biol. Chem, vol.276, issue.48, pp.44495-44501, 2001.

G. Lazennec, L. Canaple, D. Saugy, and W. Wahli, Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators, Mol. Endocrinol, vol.14, issue.12, pp.1962-1975, 2000.
URL : https://hal.archives-ouvertes.fr/inserm-00153813

G. Martin, H. Duez, C. Blanquart, V. Berezowski, P. Poulain et al., Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I, J. Clin. Invest, vol.107, issue.11, pp.1423-1432, 2001.

B. Zhang, J. Berger, G. Zhou, A. Elbrecht, S. Biswas et al., Insulin-and mitogenactivated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma, J. Biol. Chem, vol.271, issue.50, pp.31771-31774, 1996.

E. Hu, J. B. Kim, P. Sarraf, and B. M. Spiegelman, Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma, Science, vol.274, issue.5295, pp.2100-2103, 1996.

M. Adams, M. J. Reginato, D. Shao, M. A. Lazar, and V. K. Chatterjee, Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site, J. Biol. Chem, vol.272, issue.8, pp.5128-5132, 1997.

H. S. Camp, S. R. Tafuri, and T. , Leff, c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-?1 and negatively regulates its transcriptional activity, Endocrinology, vol.140, pp.392-397, 1999.

D. Shao, S. M. Rangwala, S. T. Bailey, S. L. Krakow, M. J. Reginato et al., Interdomain communication regulating ligand binding by PPAR-gamma, Nature, issue.6709, pp.377-380, 1998.

H. S. Camp and S. R. Tafuri, Regulation of peroxisome proliferatoractivated receptor gamma activity by mitogen-activated protein kinase, J. Biol. Chem, vol.272, issue.16, pp.10811-10816, 1997.

J. Han, D. P. Hajjar, J. M. Tauras, J. Feng, A. M. Gotto et al., Transforming growth factor-beta1 (TGF-beta1) and TGF-beta2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma, J. Biol. Chem, vol.275, issue.2, pp.1241-1246, 2000.

J. B. Hansen, H. Zhang, T. H. Rasmussen, R. K. Petersen, E. N. Flindt et al., Peroxisome proliferator-activated receptor delta (PPARdelta)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling, J. Biol. Chem, vol.276, issue.5, pp.3175-3182, 2001.

A. M. Krogsdam, C. A. Nielsen, S. Neve, D. Holst, T. Helledie et al., Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor delta-mediated transactivation, Biochem. J, vol.363, pp.157-165, 2002.

E. G. Mimnaugh, P. Bonvini, and L. Neckers, The measurement of ubiquitin and ubiquitinated proteins, Electrophoresis, vol.20, issue.2, pp.418-428, 1999.

M. Hodges, C. Tissot, and P. S. Freemont, Protein regulation: tag wrestling with relatives of ubiquitin, Curr. Biol, vol.8, issue.21, pp.749-752, 1998.

S. Hauser, G. Adelmant, P. Sarraf, H. M. Wright, E. Mueller et al., Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation, J. Biol. Chem, vol.24, pp.18527-18533, 2000.

C. Blanquart, O. Barbier, J. C. Fruchart, B. Staels, and C. Glineur, Peroxisome proliferator-activated receptor alpha (PPARalpha) turnover by the ubiquitin-proteasome system controls the ligandinduced expression level of its target genes, J. Biol. Chem, vol.277, issue.40, pp.37254-37259, 2002.

Z. E. Floyd and J. M. Stephens, Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes, J. Biol. Chem, vol.277, issue.6, pp.4062-4068, 2002.

P. R. Devchand, H. Keller, J. M. Peters, M. Vazquez, F. J. Gonzalez et al., The PPARalpha-leukotriene B4 pathway to inflammation control, Nature, vol.384, issue.6604, pp.39-43, 1996.

B. Staels, W. Koenig, A. Habib, R. Merval, M. Lebret et al., Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators, Nature, issue.6687, pp.790-793, 1998.

A. Madej, B. Okopien, J. Kowalski, M. Zielinski, J. Wysocki et al., Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb, Int. J. Clin. Pharmacol. Ther, vol.36, issue.6, pp.345-349, 1998.

S. M. Haffner, A. S. Greenberg, W. M. Weston, H. Chen, K. Williams et al., Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus, Circulation, vol.106, issue.6, pp.679-684, 2002.

P. Delerive, K. De, S. Bosscher, W. Besnard, J. M. Vanden-berghe et al., Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1, J. Biol. Chem, vol.274, issue.45, pp.32048-32054, 1999.

M. E. Poynter and R. A. Daynes, Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging, J. Biol. Chem, vol.273, issue.49, pp.32833-32841, 1998.

M. Kockx, P. P. Gervois, P. Poulain, B. Derudas, J. M. Peters et al., Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha, Blood, vol.93, issue.9, pp.2991-2998, 1999.

P. Gervois, N. Vu-dac, R. Kleemann, M. Kockx, G. Dubois et al., Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta, J. Biol. Chem, vol.276, issue.36, pp.33471-33477, 2001.

P. Delerive, P. Gervois, J. C. Fruchart, and B. Staels, Induction of IkappaBalpha expression as a mechanism contributing to the antiinflammatory activities of peroxisome proliferator-activated receptoralpha activators, J. Biol. Chem, vol.275, issue.47, pp.36703-36707, 2000.

N. Marx, G. K. Sukhova, T. Collins, P. Libby, and J. Plutzky, PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells, Circulation, vol.99, issue.24, pp.3125-3131, 1999.

V. Pasceri, H. D. Wu, J. T. Willerson, and E. T. Yeh, Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators, Circulation, vol.101, pp.235-238, 2000.

P. Delerive, F. Martin, G. Chinetti, F. Trottein, J. C. Fruchart et al., PPAR activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the AP-1 signalling pathways, Circ. Res, vol.85, pp.394-402, 1999.

N. Marx, B. Kehrle, K. Kohlhammer, M. Grub, W. Koenig et al., PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis, Circ. Res, vol.90, issue.6, pp.703-710, 2002.

R. Kleemann, P. P. Gervois, L. Verschuren, B. Staels, H. M. Princen et al., Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NF B-C/EBP-? complex formation, Blood, vol.101, issue.2, pp.545-551, 2003.

C. G. Su, X. Wen, S. T. Bailey, W. Jiang, S. M. Rangwala et al., A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response, J. Clin. Invest, vol.104, issue.4, pp.383-389, 1999.

A. C. Li, K. K. Brown, M. J. Silvestre, T. M. Willson, W. Palinski et al., Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice, J. Clin. Invest, vol.106, issue.4, pp.523-531, 2000.

R. Thieringer, J. E. Fenyk-melody, C. B. Le-grand, B. A. Shelton, P. A. Detmers et al., Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo, J. Immunol, vol.164, issue.2, pp.1046-1054, 2000.

S. W. Chung, B. Y. Kang, S. H. Kim, Y. K. Pak, D. Cho et al., Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-B, J. Biol. Chem, vol.275, issue.42, pp.32681-32687, 2000.

R. E. Law, W. P. Meehan, X. P. Xi, K. Graf, D. A. Wuthrich et al., Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia, J. Clin. Invest, vol.98, issue.8, pp.1897-1905, 1996.

M. Li, G. Pascual, and C. K. Glass, Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene, Mol. Cell. Biol, vol.20, issue.13, pp.4699-4707, 2000.

X. Y. Yang, L. H. Wang, T. Chen, D. R. Hodge, J. H. Resau et al., Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT, J. Biol. Chem, vol.275, issue.7, pp.4541-4544, 2000.

C. Duval, G. Chinetti, F. Trottein, J. C. Fruchart, and B. Staels, The role of PPARs in atherosclerosis, Trends Mol. Med, vol.8, issue.9, pp.422-430, 2002.